Allurion Technologies Retained Earnings (Accumulated Deficit) 2021-2024 | ALUR

Allurion Technologies retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.

Allurion Technologies Retained Earnings (Accumulated Deficit) 2021-2024 | ALUR

Allurion Technologies retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$199.9B
Stryker (SYK)$137.7B
Boston Scientific (BSX)$121.6B
Medtronic (MDT)$113B
EssilorLuxottica (ESLOY)$104.4B
Haleon (HLN)$48.1B
Lonza Group Ag (LZAGY)$45.4B
ResMed (RMD)$35B
Koninklijke Philips (PHG)$29B
Terumo (TRUMY)$27.9B
Zimmer Biomet Holdings (ZBH)$21.6B
Baxter (BAX)$20.1B
Insulet (PODD)$16.6B
Smith & Nephew SNATS (SNN)$13.4B
Bio-Rad Laboratories (BIO)$9.5B
Demant (WILYY)$9.2B
BellRing Brands (BRBR)$7.7B
Lantheus Holdings (LNTH)$7.5B
ICU Medical (ICUI)$4.3B
TG Therapeutics (TGTX)$3.9B
Haemonetics (HAE)$3.9B
Perrigo (PRGO)$3.8B
GN Store Nord (GNNDY)$3.8B
Neogen (NEOG)$3.7B
Prestige Consumer Healthcare (PBH)$3.6B
Envista Holdings (NVST)$3.3B
QuidelOrtho (QDEL)$3.1B
Agios Pharmaceuticals (AGIO)$2.6B
Maravai LifeSciences Holdings (MRVI)$2.3B
Green Thumb Industries (GTBIF)$2.2B